{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:33:26Z","timestamp":1793676806814,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adherence to scheduled physician screenings for renal function monitoring in patients with chronic kidney disease (CKD) or those at high risk remains suboptimal despite the endorsement of regular screenings by several clinical practice guidelines. Our study aims to assess the effectiveness of a point-of-care CKD screening program led by these pharmacists using the PICCOLO device while recognizing the unique position of community pharmacists in primary care. We conducted an 11-month prospective point-of-care interventional research study in the United Arab Emirates to evaluate the performance of a community pharmacist-led CKD screening program for high-risk patients. Six diverse community pharmacies were selected based on staff availability, patient volume, and their offered range of services. Eligible individuals with risk factors for CKD were identified during medication evaluations. The PICCOLO Comprehensive Metabolic Panel facilitated on-site blood analysis, delivering estimated Glomerular Filtration Rate (eGFR) results within 10 to 15 min. Data also included eGFR categories, demographic information, and insights into lifestyle and health habits collected through a questionnaire. Pharmacists conducted comprehensive medication reviews and offered referrals and lifestyle guidance as part of the program. The study encompassed a total of 400 patients, with an average age of 69\u2009\u00b1\u200913.4 years within the study cohort. Notably, 38.8% (155 individuals) of the 400 patients were found to have undiagnosed CKD stages 3\u20135. Univariate logistic regression analysis revealed a significant association between a higher incidence of CKD stages 3\u20135 and factors such as older age, a history of hypertension, vascular disease, and diabetes mellitus. In the multivariate regression model, age and a history of diabetes mellitus emerged as significant predictors of an elevated risk of CKD. This study sheds light on the viability and impact of CKD screening programs conducted by community pharmacists, particularly in detecting CKD stages 3\u20135. The findings have implications for healthcare policies, as they can influence the enhancement of early detection and management of CKD. Moreover, these insights may catalyze focused screening initiatives and strengthen collaboration between community pharmacies and healthcare systems to benefit patients at high risk of CKD.<\/jats:p>","DOI":"10.1038\/s41598-024-56765-0","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:02:51Z","timestamp":1711530171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Community pharmacist-led point-of-care eGFR screening: early detection of chronic kidney disease in high-risk patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Ammar Abdulrahman","family":"Jairoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabaa Saleh","family":"Al-Hemyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyad","family":"Shahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer H.","family":"Zyoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"El-Dahiyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"2","key":"56765_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrneph.2016.163","volume":"13","author":"RJ Glassock","year":"2017","unstructured":"Glassock, R. J., Warnock, D. G. & Delanaye, P. The global burden of chronic kidney disease: Estimates, variability and pitfalls. Nat. Rev. Nephrol. 13(2), 104\u2013114 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"56765_CR2","unstructured":"The Renal Foundation. The UK eCKD guide (2018) https:\/\/renal.org\/information-resources\/the-uk-eckd-guide\/ (Accessed 3 July 2019)."},{"key":"56765_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill, N. R. et al. Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS ONE. 11, e0158765 (2016).","journal-title":"PLoS ONE."},{"key":"56765_CR4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4103\/1319-2442.164600","volume":"26","author":"N Richards","year":"2015","unstructured":"Richards, N. et al. Epidemiology and referral patterns of patients with chronic kidney disease in the Emirate of Abu Dhabi. Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ. Transplant. Saudi Arab. 26, 1028\u20131034 (2015).","journal-title":"Saudi J. Kidney Dis. Transplant. Off. Publ. Saudi Cent. Organ. Transplant. Saudi Arab."},{"key":"56765_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010832","volume":"6","author":"S Al Shamsi","year":"2016","unstructured":"Al Shamsi, S., Dhanhani, A. A., Sheek-Hussein, M. M. & Bakoush, O. Provision of care for chronic kidney disease by non-nephrologists in a developing nation: A national survey. BMJ Open. 6, e010832 (2016).","journal-title":"BMJ Open."},{"key":"56765_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.291.7.844","volume":"291","author":"CS Fox","year":"2004","unstructured":"Fox, C. S. et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 291, 844\u2013850 (2004).","journal-title":"JAMA."},{"key":"56765_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.ki.5002017","volume":"71","author":"K Yamagata","year":"2007","unstructured":"Yamagata, K. et al. Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study. Kidney Int. 71, 159\u2013166 (2007).","journal-title":"Kidney Int."},{"key":"56765_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1258\/shorts.2011.011019","volume":"2","author":"L Alhyas","year":"2011","unstructured":"Alhyas, L., McKay, A., Balasanthiran, A. & Majeed, A. Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: Systematic review. JRSM Short Rep. 2, 55 (2011).","journal-title":"JRSM Short Rep."},{"key":"56765_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","volume":"41","author":"J Coresh","year":"2003","unstructured":"Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. & Levey, A. S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 41, 1\u201312 (2003).","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"56765_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12020-016-1014-6","volume":"55","author":"Y Shen","year":"2017","unstructured":"Shen, Y. et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: A systematic review and meta-analysis. Endocrine. 55, 66\u201376 (2017).","journal-title":"Endocrine."},{"key":"56765_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.diabres.2007.04.008","volume":"78","author":"H Saadi","year":"2007","unstructured":"Saadi, H. et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res. Clin. Pract. 78, 369\u2013377 (2007).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"56765_CR12","first-page":"1290","volume":"4","author":"B Aden","year":"2013","unstructured":"Aden, B., Karrar, S., Shafey, O. & Al Hosni, F. Cigarette, water-pipe, and medwakh smoking prevalence among applicants to Abu Dhabi\u2019s pre-marital screening program, 2011. Int. J. Prev. Med. 4, 1290\u20131295 (2013).","journal-title":"Int. J. Prev. Med."},{"key":"56765_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2105\/AJPH.2011.300290","volume":"102","author":"C Hajat","year":"2012","unstructured":"Hajat, C., Harrison, O. & Al, S. Z. Weqaya: A population-wide cardiovascular screening program in Abu Dhabi, United Arab Emirates. Am. J. Public Health. 102, 909\u2013914 (2012).","journal-title":"Am. J. Public Health."},{"key":"56765_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176540","volume":"12","author":"SG Sepanlou","year":"2017","unstructured":"Sepanlou, S. G. et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: Results of the Golestan cohort study. PLoS ONE. 12, e0176540 (2017).","journal-title":"PLoS ONE."},{"key":"56765_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOP.0b013e328336ebb0","volume":"22","author":"A Staples","year":"2010","unstructured":"Staples, A. & Wong, C. Risk factors for progression of chronic kidney disease. Curr. Opin. Pediatr. 22, 161\u2013169 (2010).","journal-title":"Curr. Opin. Pediatr."},{"key":"56765_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/kisup.2013.79","volume":"3","author":"R Kazancio\u011flu","year":"2013","unstructured":"Kazancio\u011flu, R. Risk factors for chronic kidney disease: An update. Kidney Int. Suppl. 3, 368\u2013371 (2013).","journal-title":"Kidney Int. Suppl."},{"key":"56765_CR17","first-page":"133","volume":"37","author":"LJ Brown","year":"2010","unstructured":"Brown, L. J., Clark, P. C., Armstrong, K. A., Liping, Z. & Dunbar, S. B. Identification of modifiable chronic kidney disease risk factors by gender in an African-American metabolic syndrome cohort. Nephrol. Nurs. J. J. Am. Nephrol. Nurses Assoc. 37, 133\u2013142 (2010).","journal-title":"Nephrol. Nurs. J. J. Am. Nephrol. Nurses Assoc."},{"issue":"Suppl 7","key":"56765_CR18","first-page":"57","volume":"16","author":"A Levin","year":"2001","unstructured":"Levin, A. Identification of patients and risk factors in chronic kidney disease evaluating risk factors and therapeutic strategies. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc. 16(Suppl 7), 57\u201360 (2001).","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"56765_CR19","doi-asserted-by":"publisher","first-page":"c269","DOI":"10.1159\/000321382","volume":"118","author":"RA Nugent","year":"2011","unstructured":"Nugent, R. A., Fathima, S. F., Feigl, A. B. & Chyung, D. The burden of chronic kidney disease on developing nations: A 21st century challenge in global health. Nephron Clin. Pract. 118, c269\u2013c277 (2011).","journal-title":"Nephron Clin. Pract."},{"key":"56765_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-015-0189-z","volume":"16","author":"SDS Fraser","year":"2015","unstructured":"Fraser, S. D. S. et al. The burden of comorbidity in people with chronic kidney disease stage 3: A cohort study. BMC Nephrol. 16, 193 (2015).","journal-title":"BMC Nephrol."},{"key":"56765_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003013","volume":"95","author":"W-C Tsai","year":"2016","unstructured":"Tsai, W.-C. et al. Risk factors for development and progression of chronic kidney disease: A systematic review and exploratory meta-analysis. Medicine 95, e3013 (2016).","journal-title":"Medicine"},{"issue":"1","key":"56765_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/09674845.2015.11666794","volume":"72","author":"S Muhammad","year":"2015","unstructured":"Muhammad, S. Renal point-of-care testing: Collaboration between biomedical scientists and community pharmacists. Br. J. Biomed. Sci. 72(1), 42\u201346 (2015).","journal-title":"Br. J. Biomed. Sci."},{"issue":"2","key":"56765_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","volume":"35","author":"R Thomas","year":"2008","unstructured":"Thomas, R., Kanso, A. & Sedor, J. R. Chronic kidney disease and its complications. Prim. Care. 35(2), 329\u2013344 (2008).","journal-title":"Prim. Care."},{"issue":"1","key":"56765_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3(1), 1\u2013150 (2013).","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"56765_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1592\/phco.25.1.123.55628","volume":"25","author":"AJ Zillich","year":"2005","unstructured":"Zillich, A. J. et al. Caring for patients with chronic kidney disease: A joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy 25(1), 123\u2013143 (2005).","journal-title":"Pharmacotherapy"},{"issue":"5","key":"56765_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1715163515597243","volume":"148","author":"C Curtis","year":"2015","unstructured":"Curtis, C. et al. Online clinical pathway for managing adults with chronic kidney disease. Can. Pharm. J. 148(5), 257\u2013262 (2015).","journal-title":"Can. Pharm. J."},{"issue":"1","key":"56765_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1715163515618421","volume":"149","author":"YN Al Hamarneh","year":"2016","unstructured":"Al Hamarneh, Y. N. et al. Community pharmacist targeted screening for chronic kidney disease. Can. Pharm. J. 149(1), 13\u201317 (2016).","journal-title":"Can. Pharm. J."},{"key":"56765_CR28","volume-title":"Framework for Implementation of Expanded Scope of Practice for Pharmacists","author":"Alberta Health Services","year":"2013","unstructured":"Alberta Health Services. Framework for Implementation of Expanded Scope of Practice for Pharmacists (Alberta Health Services, 2013)."},{"key":"56765_CR29","doi-asserted-by":"publisher","first-page":"c120","DOI":"10.1159\/000345149","volume":"121","author":"YMK Farag","year":"2012","unstructured":"Farag, Y. M. K., Kari, J. A. & Singh, A. K. Chronic kidney disease in the Arab world: A call for action. Nephron Clin. Pract. 121, c120\u2013c123. https:\/\/doi.org\/10.1159\/000345149 (2012).","journal-title":"Nephron Clin. Pract."},{"issue":"6","key":"56765_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199920","volume":"13","author":"S Al-Shamsi","year":"2018","unstructured":"Al-Shamsi, S., Regmi, D. & Govender, R. D. Chronic kidney disease in patients at high risk of cardiovascular disease in the United Arab Emirates: A population-based study. PLoS ONE 13(6), e0199920 (2018).","journal-title":"PLoS ONE"},{"key":"56765_CR31","unstructured":"Abaxis Inc. Piccolo\u00ae comprehensive metabolic panel (2015) https:\/\/www.abaxis.com\/sites\/default\/files\/resource-packages\/Comprehensive%20Metabolic%20Panel%20Package%20Insert-EN_0.pdf (Accessed 3 July 2019)."},{"issue":"4","key":"56765_CR32","first-page":"173","volume":"27","author":"M Peake","year":"2006","unstructured":"Peake, M. & Whiting, M. Measurement of serum creatinine\u2014current status and future goals. Clin. Biochem. Rev. 27(4), 173\u2013184 (2006).","journal-title":"Clin. Biochem. Rev."},{"issue":"6","key":"56765_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jama.2015.9425","volume":"314","author":"MR Saundes","year":"2015","unstructured":"Saundes, M. R., Cifu, A. & Vela, M. JAMA guideline synopsis: Chronic kidney disease screening. J. Am. Med. Assoc. 314(6), 615\u2013616 (2015).","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"56765_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/jcpt.12081","volume":"38","author":"AFJ Geerts","year":"2013","unstructured":"Geerts, A. F. J. et al. Feasibility of point-of-care creatinine testing in community pharmacy to monitor drug therapy in ambulatory elderly patients. J. Clin. Pharm. Ther. 38(5), 416\u2013422 (2013).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"56765_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1715163520902495","volume":"153","author":"J Donovan","year":"2020","unstructured":"Donovan, J., Al Hamarneh, Y. N., Bajorek, B., Papastergiou, J. & Tsuyuki, R. T. Community pharmacist identification of chronic kidney disease using point-of-care technology: A pilot study. Can. Pharm. J.\/Revue des Pharmaciens du Canada. 153(2), 84\u201387 (2020).","journal-title":"Can. Pharm. J.\/Revue des Pharmaciens du Canada."},{"issue":"9","key":"56765_CR36","doi-asserted-by":"publisher","first-page":"E417","DOI":"10.1503\/cmaj.120833","volume":"185","author":"P Arora","year":"2013","unstructured":"Arora, P. et al. Prevalence estimates of chronic kidney disease in Canada: Results of a nationally representative survey. CMAJ. 185(9), E417\u2013E423 (2013).","journal-title":"CMAJ."},{"issue":"5","key":"56765_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1053\/j.ajkd.2013.12.012","volume":"63","author":"P Komenda","year":"2014","unstructured":"Komenda, P. et al. Cost effectiveness of primary screening for CKD: A systematic review. Am. J. Kidney Dis. 63(5), 789\u2013797 (2014).","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"56765_CR38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2215\/CJN.11961115","volume":"11","author":"L Galbraith","year":"2016","unstructured":"Galbraith, L. et al. The see kidney disease targeted screening program for CKD. Clin. J. Am. Soc. Nephrol. 11(6), 964\u2013972 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"56765_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar, T. H. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: A meta-analysis of patient-level data. Ann. Intern. Med. 135(2), 73\u201387 (2001).","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"56765_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345(12), 851\u2013860 (2001).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"56765_CR41","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright, J. T. Jr. et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288(19), 2421\u20132431 (2002).","journal-title":"JAMA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56765-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56765-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56765-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T22:20:49Z","timestamp":1731622849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-56765-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["56765"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-56765-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"2 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7284"}}